Equities research analysts expect Codexis, Inc. (NASDAQ:CDXS) to announce $21.05 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Codexis’ earnings. The lowest sales estimate is $20.70 million and the highest is $21.70 million. Codexis reported sales of $16.07 million during the same quarter last year, which suggests a positive year-over-year growth rate of 31%. The firm is scheduled to issue its next quarterly earnings results on Tuesday, February 25th.
On average, analysts expect that Codexis will report full-year sales of $70.86 million for the current financial year, with estimates ranging from $70.50 million to $71.50 million. For the next year, analysts expect that the firm will post sales of $82.39 million, with estimates ranging from $81.50 million to $83.70 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that that provide coverage for Codexis.
Codexis (NASDAQ:CDXS) last announced its earnings results on Tuesday, November 5th. The biotechnology company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.09) by $0.10. Codexis had a negative net margin of 17.85% and a negative return on equity of 15.24%. The firm had revenue of $21.91 million for the quarter, compared to the consensus estimate of $16.56 million.
Shares of NASDAQ:CDXS traded up $0.22 during midday trading on Thursday, hitting $15.53. The company’s stock had a trading volume of 291,141 shares, compared to its average volume of 275,689. The stock has a market capitalization of $895.91 million, a price-to-earnings ratio of -73.95 and a beta of -0.01. The stock’s 50 day simple moving average is $14.61 and its 200 day simple moving average is $15.82. Codexis has a fifty-two week low of $12.68 and a fifty-two week high of $22.49. The company has a debt-to-equity ratio of 0.25, a quick ratio of 7.34 and a current ratio of 7.37.
A number of hedge funds have recently made changes to their positions in the stock. First Trust Advisors LP acquired a new position in Codexis during the second quarter valued at approximately $2,855,000. Baillie Gifford & Co. lifted its position in shares of Codexis by 4.8% in the second quarter. Baillie Gifford & Co. now owns 3,202,824 shares of the biotechnology company’s stock worth $59,028,000 after purchasing an additional 145,269 shares in the last quarter. Bank of America Corp DE lifted its position in shares of Codexis by 36.6% in the second quarter. Bank of America Corp DE now owns 57,668 shares of the biotechnology company’s stock worth $1,063,000 after purchasing an additional 15,450 shares in the last quarter. Tower Research Capital LLC TRC acquired a new position in Codexis during the second quarter worth $41,000. Finally, SG Americas Securities LLC boosted its holdings in Codexis by 1,563.8% during the third quarter. SG Americas Securities LLC now owns 171,918 shares of the biotechnology company’s stock worth $2,358,000 after purchasing an additional 161,585 shares during the last quarter. 84.93% of the stock is currently owned by institutional investors and hedge funds.
Codexis Company Profile
Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.
Recommended Story: New Google Finance Tool and Screening Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.